# A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Source: https://onco.cc/trials/nct06857175/  
OnCo record `nct06857175` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Docetaxel in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) is a phase 3 interventional study registered as NCT06857175 by Sichuan Baili Pharmaceutical Co., Ltd., with 508 participants planned, started 2025-03-25 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1 and Docetaxel or Paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06857175
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody and Platinum-based Chemotherapy
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 508

## Sources

- ClinicalTrials.gov NCT06857175: https://clinicaltrials.gov/study/NCT06857175

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06857175.json